RecruitingPhase 3NCT07168161
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Principal Investigator
- Minghui Zhao, M.D., M.DPeking University First Hospital
- Intervention
- BDB-001 injection(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Peking University International Hospital, Beijing, Beijing Municipality, China
- Beijing Tsinghua Changgung Hospital, Beijing, Beijing Municipality, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- The First Hospital of Lanzhou University, Lanzhou, Gansu, China
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
- Guangdong Provincial People's Hospital, Shenzhen, Guangdong, China
- Peking university Shenzhen Hospital, Shenzhen, Guangdong, China
- Liuzhou People's Hospital, Liuchow, Guangxi, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Guangxi Academy of Medical Sciences,The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region (gzar), China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07168161 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
- RECRUITINGEARLY PHASE1NCT07203404A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.Nanjing Bioheng Biotech Co., Ltd.
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →